Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is well-positioned for long-term revenue growth, with a strong pipeline of commercial and clinical customers in the growing cell and gene therapy market. The company also has a focus on expanding its services and products, which could lead to margin expansion in the coming years. Additionally, CryoPort's revenue visibility is high and its revenue quality is strong, providing stability for future growth.

Bears say

CryoPort is expected to see improving revenue growth driven by the recovery of the market and approvals of new cell and gene therapies. However, there are concerns about the company's ability to turn profitable as it continues to incur high operating expenses. There is also a risk of potential impairment and the stock appears overvalued compared to its peers. Ultimately, the success of CryoPort will depend on the pace of commercialization of cell and gene therapies, but the company's high valuation and operating expenses are a cause for concern.

CryoPort (CYRX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.